PHARMAC’s Largest Single Deal Sees Nine Novartis Drugs Funded
This article was originally published in PharmAsia News
Executive Summary
PHARMAC, New Zealand’s pharmaceutical management agency, signed agreements with Novartis and Biogen Idec in mid-October that sees 10 new medicines funded at reduced prices, or wider access to eight others.
You may also be interested in...
Considering Growth Options For Asian Biotechs: IPO Vs M&A
Going public via an IPO or being acquired are two ways that Asian biotech companies can grow their business, and some of the issues involved in both approaches come under discussion at a panel session at a recent conference in Singapore.
Nanjing BioPoint Shoots For 2018 Double POC Launch; Seeks $10m
A China-based IVD company, spun out of an Australian medical research institute, is seeking investors to support its plans for the 2018 launch its first two point-of-care tests for patients with infectious diseases including HIV and viral hepatitis.
Local Expertise Key To Tackling China Market: AusBiotech Meeting
Speakers from the legal, corporate and contract research sectors discussed the fast-moving changes that are impacting the legal and regulatory aspects of doing business in China at the recent AusBiotech conference in Melbourne, providing a broad range of advice for Australian and other pharma and biotech companies wanting to enter the rapidly expanding Chinese life sciences market.